Roche’s divarasib was designed offer greater potency and selectivity to KRAS G12C compared to first-generation drugs in this class marketed by Amgen and Bristol Myers Squibb. The Swiss pharma company now plans to submit the data to regulators for review as a potential treatment for non-small cell lung cancer driven by this particular mutated protein.
The post With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs appeared first on MedCity News.
